State Dispensary
Legal Review

Largest cannabis market in the world. Local approval required — many cities and counties remain banned.

First state to legalize recreational cannabis. Mature, well-regulated market with strong consumer protections.

Eliminated separate medical program in 2016. One of the highest tax rates in the country.

Oversupply has driven prices to among the lowest in the nation. Strong craft cultivation scene.

Las Vegas consumption lounges are a national first. Tourism drives significant sales volume.

Rapid market growth since Prop 207 passed in 2020. One of the fastest-growing markets in the US.

One of the most progressive social equity programs in the country. Potency-based tax structure.

One of the most competitive markets in the US. Low tax rate has driven prices down significantly.

First East Coast state with recreational sales. Strong social equity provisions and consumption site program.

Largest medical-only market in the US. Recreational legalization on 2024 ballot — failed by narrow margin.

One of the most restrictive medical programs in the US. Significant advocacy efforts ongoing for expansion.

Slow rollout due to licensing challenges. CAURD program prioritizes social equity applicants.

Significant demand from NY residents. Strong market growth since recreational sales began in 2022.

Newest recreational market. Retail sales launched in early 2025 after legalization in 2023.

Rapid transition from medical-only to recreational. Strong demand in the DC metro area.

Amendment 3 included automatic expungement — one of the most progressive provisions in any state.

Rural market with strong per-capita sales. High tax rate relative to market size.

One of the fastest recreational rollouts in the country. Strong cross-border sales from Texas.

Strong social equity program. Proximity to New York drives significant demand.

Smallest state with recreational cannabis. Compact market with strong per-capita demand.

First state to legalize through the legislature rather than a ballot initiative.

Strong caregiver program alongside retail. Tourism from Boston drives significant sales.

Remote geography limits market size. On-site consumption lounges are a unique feature.

Unique regulatory environment due to Congressional oversight. Gift economy operated for years before retail.

Newly legal state. Retail infrastructure still being established as of 2025.

Issue 2 passed November 2023. One of the largest new recreational markets by population.

One of the largest medical markets in the US. Recreational legalization efforts ongoing in legislature.

Unique pharmacy-based dispensing model. Decriminalization passed in 2021.

Recreational legalization failed at ballot in 2022. Strong medical market with growing patient base.

Small medical program. Recreational legalization failed at ballot in 2022.

Voters passed both medical and recreational in 2020; governor challenged recreational in court and won.

No smokable flower — one of the most restrictive medical programs. Advocacy for expansion ongoing.

Very limited number of dispensaries. Recreational legalization efforts ongoing in legislature.

One of the earliest medical states. Recreational legalization efforts ongoing.

Pharmacy-based dispensing model. Strong patient growth despite restrictive program.

Most dispensaries per capita in the US. Very accessible medical program with minimal restrictions.

Program launched in 2022 after voters approved Initiative 65 in 2020 (overturned then re-passed by legislature).

First Southern state to legalize recreational cannabis. High tax rate has driven some illicit market activity.

SB 47 signed March 2023. Dispensary licensing underway; first sales expected in 2025.

One of the most restrictive programs in the US. Advocacy for full medical program ongoing.

No cannabis program. CBD from hemp is legal. Significant advocacy efforts for medical program.

One of the most restrictive states. Borders Colorado and Missouri — significant cross-border purchases.

Voters approved medical cannabis in November 2024. Program infrastructure being established.

Extremely limited program. Advocacy for full medical cannabis ongoing.

Surrounded by legal states. Strong public support for legalization but legislative opposition.

No medical program. Delta-8 and hemp-derived cannabinoids widely sold.

One of the strictest states. Medical cannabis legislation has repeatedly failed.

Decriminalized possession. Medical cannabis legislation has passed the Senate but stalled.

SB 46 signed 2021. Licensing delays pushed first sales to 2024. No smokable flower permitted.

One of the most restrictive states in the country. Surrounded by legal states.

No cannabis program. Borders Colorado and Montana — cross-border purchases common.